HTCR vs SONM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HTCR exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating failure across all fundamental health benchmarks. Despite a low debt-to-equity ratio, the company suffers from severe operating losses (-65.86% operating margin) and a catastrophic long-term price collapse of -95.8% over five years. While YoY revenue growth is positive, the recent Q/Q revenue plunge of -44.36% and massive earnings misses suggest a failing business model. The stock is currently in a free-fall technical trend with no fundamental support.
The company exhibits extreme financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental health. With a Quick Ratio of 0.03 and a negative Price-to-Book ratio of -4.35, the firm is facing a severe liquidity crisis and possesses negative shareholders' equity. Catastrophic Q/Q revenue growth of -394.48% and a 5-year price decline of 99.7% suggest a business in terminal decline. The lack of an Altman Z-Score calculation is likely due to the absence of positive working capital or equity, further signaling insolvency risk.
Compare Another Pair
Related Comparisons
HTCR vs SONM: Head-to-Head Comparison
This page compares HeartCore Enterprises, Inc. (HTCR) and DNA X, Inc. (SONM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.